Bright Minds Biosciences(DRUG)
$20.51-2.10 (-9.29%)
DRUG
Bright Minds Biosciences financials statements
$20.51
At close:-2.10 (-9.29%)
Want to see DRUG full AI Analyst Report?
Bright Minds Biosciences (DRUG) Ratios
300 Followers
Bright Minds Biosciences Ratios
DRUG's free cash flow for Q3 2026 was C$-8.42M. For the 2026 fiscal year, DRUG's free cash flow was increased by C$0.00 and operating cash flow was C$-8.42M. See a summary of the company’s cash flow.
| Ratios | Sep 25 | Dec 24 | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 36.10 | 11.32 | 24.26 | 8.11 | 31.38 |
| Quick Ratio | 36.10 | 11.32 | 24.26 | 8.11 | 31.38 |
| Cash Ratio | 35.50 | 10.82 | 24.03 | 7.90 | 30.94 |
| Solvency Ratio | -5.11 | -4.80 | -25.99 | -9.83 | 0.17 |
| Operating Cash Flow Ratio | -3.72 | -3.50 | -25.01 | -9.23 | -11.46 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -23.31 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | C$ 81.93M | C$ 5.42M | C$ 6.53M | C$ 10.40M | C$ 19.40M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 |
| Debt-to-Equity Ratio | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 |
| Debt-to-Capital Ratio | 0.00 | 0.02 | 0.01 | 0.01 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.03 | 1.10 | 1.04 | 1.15 | 1.03 |
| Debt Service Coverage Ratio | 0.00 | -30.79 | -368.61 | -67.10 | 0.00 |
| Interest Coverage Ratio | 0.00 | -314.57 | -373.00 | -66.17 | 0.00 |
| Debt to Market Cap | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.03 | 0.03 | 0.15 | 0.00 |
| Net Debt to EBITDA | 6.81 | 2.06 | 0.92 | 0.78 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 101.49% | 98.43% |
| EBT Per EBIT | 87.74% | 99.58% | 100.08% | 101.51% | 98.77% |
| Return on Assets (ROA) | -14.49% | -45.90% | -107.17% | -125.65% | -42.49% |
| Return on Equity (ROE) | -14.91% | -50.61% | -111.73% | -144.06% | -43.89% |
| Return on Capital Employed (ROCE) | -16.98% | -50.46% | -111.65% | -138.89% | -45.14% |
| Return on Invested Capital (ROIC) | -16.96% | -49.07% | -110.42% | -138.00% | -44.44% |
| Return on Tangible Assets | -14.49% | -45.90% | -107.17% | -125.65% | -42.50% |
| Earnings Yield | -2.11% | -44.22% | -92.20% | -72.33% | -10.50% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.18 | 0.40 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -2027.82 | -918.45 | -75356.99 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 2027.82 | 918.45 | 75356.99 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.26 | -0.43 | -1.89 | -5.50 | -4.08 |
| Free Cash Flow Per Share | -1.26 | -0.43 | -1.89 | -5.50 | -4.08 |
| Dividend Paid and CapEx Coverage Ratio | 0.00 | -462546.50 | -1404853.00 | 0.00 | 0.00 |
| Capital Expenditure Coverage Ratio | 0.00 | -462546.50 | -1404853.00 | 0.00 | 0.00 |
| Operating Cash Flow Coverage Ratio | -69.10 | -15.55 | -95.50 | -97.11 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -1.50% | -29.20% | -87.85% | -64.71% | -9.02% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -47.44 | -2.26 | -1.08 | -1.38 | -9.53 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 7.08 | 1.14 | 1.21 | 1.99 | 4.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -66.82 | -3.42 | -1.14 | -1.55 | -11.08 |
| Price-to-Operating Cash Flow Ratio | -66.82 | -3.42 | -1.14 | -1.55 | -11.08 |
| Price-to-Earnings Growth (PEG) Ratio | -0.27 | 0.03 | 0.02 | -0.05 | -0.01 |
| Enterprise Value Multiple | -40.98 | -0.27 | -0.18 | -0.65 | 0.00 |
| Enterprise Value | 497.97M | 734.81K | 1.32M | 9.51M | 61.37M |
| EV to EBITDA | -40.98 | -0.27 | -0.18 | -0.65 | 0.00 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -57.29 | -0.40 | -0.19 | -0.70 | -8.38 |
| EV to Operating Cash Flow | -57.29 | -0.40 | -0.19 | -0.70 | -8.38 |
| Tangible Book Value Per Share | 11.93 | 1.28 | 1.77 | 4.27 | 10.81 |
| Shareholders’ Equity Per Share | 11.93 | 1.28 | 1.77 | 4.27 | 10.81 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | -0.01 | 0.02 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -1.78 | -0.65 | -1.98 | -6.15 | -4.74 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.01 | 0.98 |
| Interest Burden | 1.00 | 1.00 | 1.00 | 1.02 | 1.00 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.71 | 0.66 | 0.95 | 0.91 | 0.85 |
Currency in CAD

